Fulltext

Acquired hemophilia as first manifestation of breast carcinoma in a man under long-term spironolactone therapy

Lamy, Olivier ; Elmiger, Hubert ; Fiche, Maryse ; Bauer, Jean ; Livio, FranÇoise

In: International Journal of Clinical Oncology, 2004, vol. 9, no. 2, p. 130-133

Zum persönliche Liste hinzufügen
    Titel
    • Acquired hemophilia as first manifestation of breast carcinoma in a man under long-term spironolactone therapy
    Autor
    • Lamy, Olivier. Service of Medicine A, Department of Internal Medicine, University Hospital, CHUV, BH10, CH-1011, Lausanne, Switzerland
    • Elmiger, Hubert. Service of Medicine A, Department of Internal Medicine, University Hospital, CHUV, BH10, CH-1011, Lausanne, Switzerland
    • Fiche, Maryse. Department of Pathology, University Hospital, Lausanne, Switzerland
    • Bauer, Jean. Oncology Center, Department of Internal Medicine, University Hospital, Lausanne, Switzerland
    • Livio, FranÇoise. Division of Clinical Pharmacology, Department of Internal Medicine, University Hospital, Lausanne, Switzerland
    Dokumententyp
    • Postprint
    Sprache
    • Englisch
    Veröffentlicht in
    • International Journal of Clinical Oncology, 2004, vol. 9, no. 2, p. 130-133. Springer-Verlag
    Andere elektronische Ausgabe
    OAI-PMH-ID
    • oai:doc.rero.ch:312887
    Summary
    A 69-year-old man under long-term spironolactone therapy (16 years) was hospitalized with spontaneous hematoma on the trunk and extremities. Coagulation studies disclosed an acquired hemophilia that was successfully treated with human factor VIII for a few days and immunosuppressive agents for several months. Physical examination revealed bilateral gynecomastia and an upper left quadrant breast nodule. Complete staging was unremarkable. Complete left mastectomy was performed. Histopathology showed invasive ductal carcinoma, expressing positivity for estrogen and progesterone receptors. The acquired hemophilia was considered to be a paraneoplasic syndrome. The question of a linkage between long-term spironolactone therapy and breast carcinoma is discussed